Key result
N3PUFAs show potential as an adjuvant COVID-19 treatment driven by lower thrombotic risk.
Why the study?
The excellent safety profile and cardiovascular benefits of omega-3 polyunsaturated fatty acids make them a prospective adjuvant treatment for individuals at higher risk of cardiovascular complications associated with COVID-19.
Do omega-3 polyunsaturated fatty acids improve cardiovascular health and reduce thrombotic outcomes in people at higher risk of cardiovascular problems associated with COVID-19?
Do omega-3 polyunsaturated fatty acids improve cardiovascular health and reduce thrombotic outcomes in people at higher risk of cardiovascular problems associated with COVID-19?
Dietary N3PUFAs may serve as a safe, prospective adjuvant treatment to mitigate cardiovascular risks and thrombotic complications associated with COVID-19.
Hypothesis-generating for N3PUFAs in COVID-19 thrombotic risk; randomized trials needed before clinical adoption.
The accumulating literature demonstrates that omega-3 polyunsaturated fatty acid (n-3 polyunsaturated fatty acid, N3PUFA) can be incorporated into the phospholipid bilayer of cell membranes in the human body to positively affect the cardiovascular system, including improving epithelial function, decreasing coagulopathy, and attenuating uncontrolled inflammatory responses and oxidative stress. Moreover, it has been proven that the N3PUFAs, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are precursors of some potent endogenous bioactive lipid mediators that mediate some favorable effects attributed to their parent substances. A dose-response relationship between increased EPA and DHA intake and reduced thrombotic outcomes has been reported. The excellent safety profile of dietary N3PUFAs makes them a prospective adjuvant treatment for people exposed to a higher risk of cardiovascular problems associated with COVID-19. This review presented the potential mechanisms that might contribute to the beneficial effects of N3PUFA and the optimal form and dose applied.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2023) conducted a review in Cardiovascular health associated with COVID-19. Omega-3 Polyunsaturated Fatty Acids (N3PUFAs) was evaluated. Omega-3 polyunsaturated fatty acids (N3PUFAs) demonstrate potential cardiovascular benefits, including reduced thrombotic risk, serving as a prospective adjuvant treatment for COVID-19.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: